Fate of billions for opioid victims from Sacklers rests with high court
The Supreme Court will hear oral argument Monday on the remaining sticking point in the years-long effort to settle litigation against Purdue Pharma.
Stay updated with breaking news from Us Trustee Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Supreme Court will hear oral argument Monday on the remaining sticking point in the years-long effort to settle litigation against Purdue Pharma.
On Monday, the Supreme Court will take on one of its highest-profile bankruptcy cases in recent memory: Whether or not to approve OxyContin-maker Purdue Pharma’s controversial agreement that would give billions of dollars to victims of the opioid epidemic while protecting members of the Sackler family, who owned the company, from current and future opioid-related civil lawsuits.
Supreme court to review immunity of Sacklers from prosecution under a 2019 bankruptcy settlement with the OxyContin maker
In 2014, when the first opioid lawsuits were filed against Purdue Pharma, Tiffinee Scott’s daughter was still years away from her fatal overdose from addictive prescription painkillers, including Purdue’s OxyContin, which she was taking to manage sickle cell pain. That year, Dede Yoder’s teenage son was struggling with an addiction that began with an OxyContin prescription for a sports injury. He would die from an overdose in 2017, after attempting rehab eight times. It would be years before Gar
Purdue Pharma has said there will be no $6 billion opioid crisis settlement without releasing Sackler family members from liability